MBIO Mustang Bio Inc.

-0.04  -1%
Previous Close 3.4
Open 3.4
Price To Book 4.73
Market Cap 135,270,969
Shares 40,259,217
Volume 68,767
Short Ratio
Av. Daily Volume 363,386

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 next readout due 4Q 2019.
Acute myeloid leukemia
Phase 1 readout due 2019.
Phase 1 trial initiation announced October 30, 2018.
CAR-T therapy
HER2-positive breast cancer
Phase 1/2 trial ongoing. Initial data noted in NEJM.
X-linked Severe Combined Immunodeficiency (XSCID)
Phase 1 initial data due 2019.
B-cell Non-Hodgkin Lymphoma & Chronic Lymphocytic Leukemia (CLL)
Phase 1/2 trial to be initiated late 2019 or 2020.
Multiple myeloma

Latest News

  1. The Mustang Bio (NASDAQ:MBIO) Share Price Is Down 52% So Some Shareholders Are Wishing They Sold
  2. Mustang Bio and St. Jude Children’s Research Hospital to Participate in Panel Discussion at Boston CEO 2019
  3. Mustang Bio and Nationwide Children’s Hospital Receive Orphan Drug Designation for MB-108 (Oncolytic Virus C134) for the Treatment of Malignant Glioma
  4. Mustang Bio to Present at the Cell & Gene Therapy USA Congress 2019
  5. Mustang Bio Reports First Quarter 2019 Financial Results and Recent Corporate Highlights
  6. Mustang Bio Announces Full Exercise of Option
  7. Mustang Bio Announces City of Hope Opens First-of-Its-Kind Multiple Myeloma CAR T Cell Therapy Trial Targeting CS1 Protein
  8. Mustang Bio Announces Pricing of Public Offering of Common Stock
  9. The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering
  10. Mustang Bio Announces Proposed Public Offering of Common Stock
  11. FDA Events Put Healthcare Stocks In The Headlines: Here's One That No One's Talking About Yet
  12. Is Mustang Bio the Next Great Biotech Stock?
  13. Mustang Bio News: MBIO Stock Skyrockets on New ‘Bubble Boy’ Therapy
  14. Why Mustang Bio Stock Is On Fire Today
  15. The Daily Biotech Pulse: Hookipa To Debut, Mustang Bio Skyrockets, AngioDynamics Sheds Portfolio
  16. Mustang Bio's stock soars to near 4-fold gain after deal to commercialize 'bubble boy' disease treatment
  17. Behind the licensing deal for St. Jude's 'bubble boy' disease cure
  18. St. Jude Children’s Research Hospital publishes results of Lentiviral Gene Therapy for Treatment of Infants with X-linked Severe Combined Immunodeficiency in New England Journal of Medicine